Overview: Gamma-Glutamyl Transferase (GGT) Marker Rapid TestIntroduction: The Gamma-Glutamyl Transferase (GGT) Marker Rapid Test is a diagnostic tool designed to detect GGT levels in serum or plasma samples, facilitating the screening of liver dysfunction. Associated with conditions like alcoholic liver disease or cholestasis, this metabolic disorder presents with jaundice, fatigue, and severe complications like cirrhosis if untreated, particularly in individuals with alcohol use or hepatitis. Per the 2023 American Association for the Study of Liver Diseases guidelines, the test employs immunochromatographic technology, delivering results within 15-20 minutes with reasonable sensitivity and specificity, making it a valuable tool for initial screening in hepatology settings. This rapid diagnostic falls under biochemistry and targets individuals with hepatic symptoms or metabolic risk factors, addressing the challenge of early detection to guide lifestyle changes or medication. With morbidity rates elevated due to underdiagnosis, the test supports public health efforts by enabling early identification, facilitating treatment, and reducing complications. Its multi-sample capability enhances its utility.Other Names: GGT Rapid Test.FDA Status: FDA approved, CLIA certified for biochemistry, compliant with 2025 standards.Historical Milestone: Introduced in the 2000s by Roche, this test advanced liver marker detection, providing a rapid alternative to traditional assays.Purpose: The test screens for GGT to guide liver dysfunction diagnosis, assess hepatic status, and inform treatment and prevention strategies.Test Parameters: Presence of GGT, detected with reasonable specificity to indicate liver damage, typically detectable in serum or plasma at elevated levels during active disease.Pretest Condition: No fasting required; patients should avoid food or drink for 30 minutes prior to collection to ensure sample integrity, and they should report jaundice, fatigue, or recent alcohol use.Specimen: Serum 2-5 mL, Plasma 2-4 mL, collected using sterile SST or EDTA tubes, transported within 24 hours to maintain sample viability.Sample Stability at Room Temperature: 24 hours with proper handling in a cool environment to preserve marker integrity, ensuring reliable test performance.Sample Stability at Refrigeration: 24 hours at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.Sample Stability at Frozen: Not recommended, as freezing may degrade markers, increasing the risk of false negatives and compromising diagnostic accuracy.Medical History: Patients should provide details on jaundice, fatigue, abdominal pain, or prior liver issues, as well as any family history of hepatic disease or recent alcohol use.Consent: Written informed consent is required, detailing the test's purpose, potential risks of untreated dysfunction including cirrhosis, benefits of early detection, and minimal discomfort from sample collection.Procedural Considerations: The test utilizes an immunochromatographic cassette requiring trained personnel to ensure sterile technique, avoid hemolysis or contamination, and interpret results within 15-20 minutes using provided positive and negative controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols, and store test kits according to manufacturer specifications to ensure reliability.Factors Affecting Result Accuracy: Delays beyond 24 hours, improper storage conditions, cross-contamination with other samples, or recent medication use can affect results. Correlation with ALT or imaging is recommended to confirm findings.Clinical Significance: A positive result indicates possible liver dysfunction, necessitating further investigation like ALT levels or hepatology consultation. A negative result may require follow-up testing if symptoms persist, especially if sampled during stable periods.Specialist Consultation: Hepatologists should be consulted for case management, treatment planning, and coordination with liver disease programs.Additional Supporting Tests: ALT, AST, or ultrasound for confirmation.Test Limitations: The test may produce false positives in alcohol use or false negatives in early disease, requiring a comprehensive diagnostic approach that includes clinical correlation.References: AASLD Guidelines 2023, Journal of Hepatology 2024, Biochemistry 2025.